CytomX teams up with Amgen to develop EGFR-targeting antibodies for cancer [Seeking Alpha]
CytomX Therapeutics, Inc. (CTMX)
Last cytomx therapeutics, inc. earnings: 11/7 04:09 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.cytomx.com
Company Research
Source: Seeking Alpha
CytomX teams up with Amgen to develop EGFR-targeting antibodies for cancerCytomX Therapeutics (NASDAQ:CTMX) inks astrategic collaboration with Amgen (NASDAQ:AMGN) to co-develop a CytomX Probody T-cell engaging bispecific against the well-validated cancer target Epidermal Growth Factor Receptor (EGFR).Probody T-cell engaging bispecifics are antibody constructs that the company says are capable of directing cytotoxic T cells in tumor microenvironments. In preclinical studies, CytomX's Probody versions of EGFRxCD3 bispecific therapeutics induced tumor regressions and increased the therapeutic window for the target.Under the terms of the partnership, the companies will co-develop a Probody T-cell engaging bispecific against EGFRxCD3. CytomX will lead early development with Amgen taking over later development and commercialization. Global late-stage development costs will be shared. Amgen will pay $40M upfront and purchase $20M of CTMX common stock. CytomX will be eligible for up to $455M
Show less
Read more
Impact Snapshot
Event Time:
CTMX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CTMX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CTMX alerts
High impacting CytomX Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CTMX
News
- CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors [Yahoo! Finance]Yahoo! Finance
- CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid TumorsGlobeNewswire
- CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas [Yahoo! Finance]Yahoo! Finance
- CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with AstellasGlobeNewswire
- CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors [Yahoo! Finance]Yahoo! Finance
CTMX
Earnings
- 11/7/23 - Beat
CTMX
Sec Filings
- 4/4/24 - Form DEFA14A
- 4/4/24 - Form DEF
- 3/28/24 - Form 4
- CTMX's page on the SEC website